| Dr James Malcolm Bunch, PHARM D | |
|
700 Chief Eddie Hoffman Hwy., Bethel, AK 99559 | |
| (907) 543-6653 | |
| Not Available |
| Full Name | Dr James Malcolm Bunch |
|---|---|
| Gender | Male |
| Speciality | Pharmacist |
| Location | 700 Chief Eddie Hoffman Hwy., Bethel, Alaska |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1548341639 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 1592 (Alaska) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr James Malcolm Bunch, PHARM D Po Box 3391, Bethel, AK 99559-3391 Ph: (907) 543-6652 | Dr James Malcolm Bunch, PHARM D 700 Chief Eddie Hoffman Hwy., Bethel, AK 99559 Ph: (907) 543-6653 |
News Archive
The intestinal hormone secretin, considered by some to be a promising drug in the treatment of autism, does not improve the symptoms and should not be used to treat the disorder, according to a new review of studies.
Following weeks of criticism over his administration's COVID-19 response, President Donald Trump pulled out new statistics to claim the nation is actually among the best in the world in fighting the lethal coronavirus.
Researchers at Umeå University in Sweden have performed a study that indicates that neither blood flow nor the flow of spinal fluid in the brain contribute to the development of multiple sclerosis, MS. The findings run directly counter to a much-discussed and widely spread Italian theory.
Affymetrix, Inc. today reported that based on preliminary financial data, the Company expects total revenue for the second quarter of 2010 to be in the range of $71-72 million, as compared to the Company's previous guidance in the range of $80-82 million. The company expects product revenue for the second quarter of 2010 to be approximately $65-66 million, including instrument sales of approximately $4-5 million and consumable sales of approximately $60-61 million.
Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has accepted for review the Biologics License Application (BLA) for MK-3475, Merck's investigational anti-PD-1 antibody, for the treatment of unresectable or metastatic melanoma in patients who have been previously treated with ipilimumab.
› Verified 1 days ago
Dr. Alicia Paula Koffi, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 700 Chief Eddie Hoffman Highway, Bethel, AK 99559 Phone: 907-543-6300 Fax: 907-543-6620 | |
Melanie J. Gibson, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 700 Chief Eddie Hoffman Highway, Bethel, AK 99559 Phone: 907-543-6992 Fax: 907-543-6306 | |
Dr. Heather Heidorn, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 528 Chief Eddie Hoffman Hwy, Bethel, AK 99559 Phone: 907-543-6133 | |
Yinka Falana, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 700 Chief Eddie Hoffman Hwy, Bethel, AK 99559 Phone: 907-543-6000 | |
Dr. Bridget N Alem, PHARM D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 700 Eddie Hoffman Hwy., Bethel, AK 99559 Phone: 907-543-6552 | |
Elizabeth Kelly Tressler, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 700 Chief Eddie Hoffman Highway, Pharmacy, Bethel, AK 99559 Phone: 907-543-6652 | |
Dr. Dustin Edward Boller, PHARM. D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 700 Cheif Eddie Hoffman Highway, Bethel, AK 99559 Phone: 907-543-6653 Fax: 907-543-6306 |